Cargando…

MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4

Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease associated with dysfunction of pulmonary artery endothelial cells and pulmonary artery smooth muscle cells (PASMCs). To explore the potential mechanism of miR-193-3p in pulmonary arterial hypertension, human PASMCs and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhenhua, Geng, Jie, Qi, Yujuan, Li, Jian, Bai, Yaobang, Guo, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734527/
https://www.ncbi.nlm.nih.gov/pubmed/33354317
http://dx.doi.org/10.1177/2045894020974919
_version_ 1783622489892454400
author Wu, Zhenhua
Geng, Jie
Qi, Yujuan
Li, Jian
Bai, Yaobang
Guo, Zhigang
author_facet Wu, Zhenhua
Geng, Jie
Qi, Yujuan
Li, Jian
Bai, Yaobang
Guo, Zhigang
author_sort Wu, Zhenhua
collection PubMed
description Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease associated with dysfunction of pulmonary artery endothelial cells and pulmonary artery smooth muscle cells (PASMCs). To explore the potential mechanism of miR-193-3p in pulmonary arterial hypertension, human PASMCs and rats were respectively stimulated by hypoxia and monocrotaline to establish PAH model in vivo and in vitro. The expressions of miR-193-3p and p21-activated protein kinase 4 (PAK4) in the lung samples of PAH patients and paired healthy samples from the healthy subjects in PHA cells and rats were detected by quantitative reverse transcriptase-PCR. Morphological changes in lung tissues were determined using hematoxylin and eosin staining. Right ventricular systolic pressure (RVSP) and ratio of right ventricle to left ventricle plus septum (RV/LV p S) were measured. The binding relationship between miR-193-3p and PAK4 was analyzed by TargetScan and verified by luciferase reporter assay. Cell viability, apoptosis, and migration were detected by 3-(4, 5-Dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide (MTT) flow cytometry, and wound-healing assays, respectively. The protein expressions of PAK4, proliferating cell nuclear antigen (PCNA), P21, p-AKT, and AKT in vivo or in vitro were determined by Western blot. In this study, we found that in pulmonary arterial hypertension, miR-193-3p expression was downregulated and PAK4 expression was up-regulated. MiR-193-3p directly targeted PAK4 and negatively regulated its expression. Hypoxia condition promoted cell proliferation, migration, and inhibited apoptosis accompanied with increased expressions of PCNA and p-AKT/AKT and decreased expression of P21 in PASMCs. MiR-193-3p overexpression attenuated the effects of hypoxia on PASMCs via downregulating PAK4. Monocrotaline treatment increased p-AKT/AKT and decreased P21 expression and caused pulmonary vascular remodeling in the model rats. MiR-193-3p overexpression attenuated pulmonary vascular remodeling, decreased p-AKT/AKT, and increased P21 levels via downregulating PAK4 in monocrotaline-induced rats. The results in this study demonstrated that upregulation of miR-193-3p reduced cell proliferation, migration, and apoptosis of PAH in vitro and pulmonary vascular remodeling in PAH in vivo through downregulating PAK4.
format Online
Article
Text
id pubmed-7734527
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77345272020-12-21 MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4 Wu, Zhenhua Geng, Jie Qi, Yujuan Li, Jian Bai, Yaobang Guo, Zhigang Pulm Circ Original Research Article Pulmonary arterial hypertension (PAH) is a progressive pulmonary vascular disease associated with dysfunction of pulmonary artery endothelial cells and pulmonary artery smooth muscle cells (PASMCs). To explore the potential mechanism of miR-193-3p in pulmonary arterial hypertension, human PASMCs and rats were respectively stimulated by hypoxia and monocrotaline to establish PAH model in vivo and in vitro. The expressions of miR-193-3p and p21-activated protein kinase 4 (PAK4) in the lung samples of PAH patients and paired healthy samples from the healthy subjects in PHA cells and rats were detected by quantitative reverse transcriptase-PCR. Morphological changes in lung tissues were determined using hematoxylin and eosin staining. Right ventricular systolic pressure (RVSP) and ratio of right ventricle to left ventricle plus septum (RV/LV p S) were measured. The binding relationship between miR-193-3p and PAK4 was analyzed by TargetScan and verified by luciferase reporter assay. Cell viability, apoptosis, and migration were detected by 3-(4, 5-Dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide (MTT) flow cytometry, and wound-healing assays, respectively. The protein expressions of PAK4, proliferating cell nuclear antigen (PCNA), P21, p-AKT, and AKT in vivo or in vitro were determined by Western blot. In this study, we found that in pulmonary arterial hypertension, miR-193-3p expression was downregulated and PAK4 expression was up-regulated. MiR-193-3p directly targeted PAK4 and negatively regulated its expression. Hypoxia condition promoted cell proliferation, migration, and inhibited apoptosis accompanied with increased expressions of PCNA and p-AKT/AKT and decreased expression of P21 in PASMCs. MiR-193-3p overexpression attenuated the effects of hypoxia on PASMCs via downregulating PAK4. Monocrotaline treatment increased p-AKT/AKT and decreased P21 expression and caused pulmonary vascular remodeling in the model rats. MiR-193-3p overexpression attenuated pulmonary vascular remodeling, decreased p-AKT/AKT, and increased P21 levels via downregulating PAK4 in monocrotaline-induced rats. The results in this study demonstrated that upregulation of miR-193-3p reduced cell proliferation, migration, and apoptosis of PAH in vitro and pulmonary vascular remodeling in PAH in vivo through downregulating PAK4. SAGE Publications 2020-12-10 /pmc/articles/PMC7734527/ /pubmed/33354317 http://dx.doi.org/10.1177/2045894020974919 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Wu, Zhenhua
Geng, Jie
Qi, Yujuan
Li, Jian
Bai, Yaobang
Guo, Zhigang
MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4
title MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4
title_full MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4
title_fullStr MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4
title_full_unstemmed MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4
title_short MiR-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting PAK4
title_sort mir-193-3p attenuates the vascular remodeling in pulmonary arterial hypertension by targeting pak4
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734527/
https://www.ncbi.nlm.nih.gov/pubmed/33354317
http://dx.doi.org/10.1177/2045894020974919
work_keys_str_mv AT wuzhenhua mir1933pattenuatesthevascularremodelinginpulmonaryarterialhypertensionbytargetingpak4
AT gengjie mir1933pattenuatesthevascularremodelinginpulmonaryarterialhypertensionbytargetingpak4
AT qiyujuan mir1933pattenuatesthevascularremodelinginpulmonaryarterialhypertensionbytargetingpak4
AT lijian mir1933pattenuatesthevascularremodelinginpulmonaryarterialhypertensionbytargetingpak4
AT baiyaobang mir1933pattenuatesthevascularremodelinginpulmonaryarterialhypertensionbytargetingpak4
AT guozhigang mir1933pattenuatesthevascularremodelinginpulmonaryarterialhypertensionbytargetingpak4